Completed PHASE2 INTERVENTIONAL NCT00134693

A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis

A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship

Sponsor: GlaxoSmithKline

Conditions Arthritis, Rheumatoid

Interventions Prednisolone SB-681323

Updated 7 times since 2017 Last updated: Jul 27, 2017 Started: Jun 21, 2005 Primary completion: Aug 3, 2006 Completion: Aug 3, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00134693, this PHASE2 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Sep 2017 [monthly]

Completed PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Berlin, Germany , Cambridge, United Kingdom , Chemnitz, Germany , Darlinghurst, Australia , Daw Park, Australia , Douglas, Australia , Hildesheim, Germany , Hobart, Australia , Leipzig, Germany and 14 more locations